GRCL
Gracell Biotechnologies Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$989.87M
P/E Ratio
—
EPS
$-0.97
Beta
-0.34
52W High
$525.25
52W Low
$306.65
50-Day MA
$9.54
200-Day MA
$5.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 366,000 |
| EBITDA | $-509.64M |
| Operating Margin | 0.00% |
| Return on Equity | -31.60% |
| Return on Assets | -19.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $16.90 |
| Price-to-Book | 4.39 |
| Price-to-Sales (TTM) | 732.21 |
| EV/Revenue | 150.04 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $96.57M |
| Float | $165.04M |
| % Insiders | 16.39% |
| % Institutions | 63.11% |
Data last updated: 4/8/2026